BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, April 17, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2004

View Archived Issues

Long-acting dipeptidyl-peptidase IV inhibitor ameliorates insulin resistance

Read More

New data on the use of SC-1 in the treatment of gastric cancer

Read More

Tocosol paclitaxel found safe and effective against advanced tumors in humans

Read More

Phase II trials of Levulan PDT in high-grade dysplasia in Barrett's esophagus and facial photodamage

Read More

Bradley Pharmaceuticals to acquire Bioglan

Read More

Enrollment opens in pivotal trial of doripenem for hospital-acquired pneumonia

Read More

Enrollment completed in Angiotech vascular wrap study

Read More

Completion of phase IIa study of AeroLEF in postsurgical patients

Read More

CytRx completes licensing deal with SynthRx

Read More

Oblimersen sodium reported to increase the antitumor efficacy of dacarbazine in malignant melanoma

Read More

Results of phase III trials of rimonabant in metabolic syndrome and smoking presented

Read More

Combined drug therapy reduces cocaine use with limited abuse potential in primates

Read More

Novel dual PPAR agonist with hypoglycemic and hypolipidemic effects

Read More

MMP inhibitor BAY-15-7496 shows potential for the treatment of COPD

Read More

Disappointing results from emfilermin proof-of-concept study

Read More

Phase I/II study for Merix's renal cancer vaccine

Read More

Altocor product name changed to Altoprev

Read More

PRECISE study to evaluate PhosLo plus Lipitor combination therapy

Read More

Astex Technology extends structural biology research agreement with Aventis

Read More

Ganymed licenses WT1 immunotherapy rights to Corixa and Kirin Brewery

Read More

Leo Pharma shuts HL-10 phase III study

Read More

LigoCyte executes norovirus vaccine agreement with Baylor College of Medicine

Read More

Incyte offers drug discovery and development update

Read More

Corixa highlights first quarter accomplishments

Read More

Non-calcemic vitamin D analogues for use in secondary hyperparathyroidism

Read More

New Rho kinase inhibitors in early development at Bayer

Read More

Two series of beta2-adrenoceptor agonists patented by GSK researchers

Read More

Two series of MCH antagonists identified at Boehringer Ingelheim

Read More

Bayer scientists present novel CETP inhibitors

Read More

Inhibitors of prostaglandin and leukotriene production developed at Wakamoto

Read More

Boehringer Ingelheim scientists describe new beta3-adrenoceptor agonists

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 17, 2026.
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 14, 2026
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing